Category: Toxicology
Keywords: dabigatran, bleeding, idarucizumab, reversal (PubMed Search)
Posted: 7/6/2015 by Bryan Hayes, PharmD
(Updated: 7/9/2015)
Click here to contact Bryan Hayes, PharmD
The New England Journal of Medicine and Lancet both published studies evaluating idarucizumab for reversal of dabigatran. It is a monoclonal antibody fragment that binds dabigatran with high affinity. Dr. Ryan Radecki summarizes the two articles on his EM Lit of Note blog.
Here are a few take home points from these early studies:
Pollack CV, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015 Jun 22. [Epub ahead of print, PMID 26095746]
Glund S, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in health male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015 Jun 15. [Epub ahead of print, PMID 26088268]
Follow me on Twitter (@PharmERToxGuy) or Google Plus (+bryanhayes13)